231 related articles for article (PubMed ID: 18855422)
1. Substrate inhibition kinetic model for West Nile virus NS2B-NS3 protease.
Tomlinson SM; Watowich SJ
Biochemistry; 2008 Nov; 47(45):11763-70. PubMed ID: 18855422
[TBL] [Abstract][Full Text] [Related]
2. Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction.
Wichapong K; Pianwanit S; Sippl W; Kokpol S
J Mol Recognit; 2010; 23(3):283-300. PubMed ID: 19693793
[TBL] [Abstract][Full Text] [Related]
3. Cleavage preference distinguishes the two-component NS2B-NS3 serine proteinases of Dengue and West Nile viruses.
Shiryaev SA; Kozlov IA; Ratnikov BI; Smith JW; Lebl M; Strongin AY
Biochem J; 2007 Feb; 401(3):743-52. PubMed ID: 17067286
[TBL] [Abstract][Full Text] [Related]
4. Homology modeling and molecular dynamics study of West Nile virus NS3 protease: a molecular basis for the catalytic activity increased by the NS2B cofactor.
Zhou H; Singh NJ; Kim KS
Proteins; 2006 Nov; 65(3):692-701. PubMed ID: 16972281
[TBL] [Abstract][Full Text] [Related]
5. Phosphonate inhibitors of West Nile virus NS2B/NS3 protease.
Skoreński M; Milewska A; Pyrć K; Sieńczyk M; Oleksyszyn J
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):8-14. PubMed ID: 30362835
[TBL] [Abstract][Full Text] [Related]
6. Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication.
Kouretova J; Hammamy MZ; Epp A; Hardes K; Kallis S; Zhang L; Hilgenfeld R; Bartenschlager R; Steinmetzer T
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):712-721. PubMed ID: 28385094
[TBL] [Abstract][Full Text] [Related]
7. STD-NMR experiments identify a structural motif with novel second-site activity against West Nile virus NS2B-NS3 protease.
Schöne T; Grimm LL; Sakai N; Zhang L; Hilgenfeld R; Peters T
Antiviral Res; 2017 Oct; 146():174-183. PubMed ID: 28927677
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the West Nile virus protease substrate specificity and inhibitors.
Mueller NH; Yon C; Ganesh VK; Padmanabhan R
Int J Biochem Cell Biol; 2007; 39(3):606-14. PubMed ID: 17188926
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease.
Nall TA; Chappell KJ; Stoermer MJ; Fang NX; Tyndall JD; Young PR; Fairlie DP
J Biol Chem; 2004 Nov; 279(47):48535-42. PubMed ID: 15322074
[TBL] [Abstract][Full Text] [Related]
10. Profiling of flaviviral NS2B-NS3 protease specificity provides a structural basis for the development of selective chemical tools that differentiate Dengue from Zika and West Nile viruses.
Rut W; Groborz K; Zhang L; Modrzycka S; Poreba M; Hilgenfeld R; Drag M
Antiviral Res; 2020 Mar; 175():104731. PubMed ID: 32014497
[TBL] [Abstract][Full Text] [Related]
11. Site-directed mutagenesis and kinetic studies of the West Nile Virus NS3 protease identify key enzyme-substrate interactions.
Chappell KJ; Nall TA; Stoermer MJ; Fang NX; Tyndall JD; Fairlie DP; Young PR
J Biol Chem; 2005 Jan; 280(4):2896-903. PubMed ID: 15494419
[TBL] [Abstract][Full Text] [Related]
12. Breathing new life into West Nile virus therapeutics; discovery and study of zafirlukast as an NS2B-NS3 protease inhibitor.
Martinez AA; Espinosa BA; Adamek RN; Thomas BA; Chau J; Gonzalez E; Keppetipola N; Salzameda NT
Eur J Med Chem; 2018 Sep; 157():1202-1213. PubMed ID: 30193218
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and in vitro evaluation of West Nile virus protease inhibitors based on the 2-{6-[2-(5-phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide scaffold.
Samanta S; Lim TL; Lam Y
ChemMedChem; 2013 Jun; 8(6):994-1001. PubMed ID: 23619931
[TBL] [Abstract][Full Text] [Related]
14. West Nile Virus (WNV) protease and membrane interactions revealed by NMR spectroscopy.
Gayen S; Chen AS; Huang Q; Kang C
Biochem Biophys Res Commun; 2012 Jul; 423(4):799-804. PubMed ID: 22713461
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vitro evaluation of West Nile virus protease inhibitors based on the 1,3,4,5-tetrasubstituted 1H-pyrrol-2(5H)-one scaffold.
Gao Y; Samanta S; Cui T; Lam Y
ChemMedChem; 2013 Sep; 8(9):1554-60. PubMed ID: 23868614
[TBL] [Abstract][Full Text] [Related]
16. Context-Dependent Cleavage of the Capsid Protein by the West Nile Virus Protease Modulates the Efficiency of Virus Assembly.
VanBlargan LA; Davis KA; Dowd KA; Akey DL; Smith JL; Pierson TC
J Virol; 2015 Aug; 89(16):8632-42. PubMed ID: 26063422
[TBL] [Abstract][Full Text] [Related]
17. Detection and in-cell selectivity profiling of the full-length West Nile virus NS2B/NS3 serine protease using membrane-anchored fluorescent substrates.
Condotta SA; Martin MM; Boutin M; Jean F
Biol Chem; 2010 May; 391(5):549-59. PubMed ID: 20302513
[TBL] [Abstract][Full Text] [Related]
18. West Nile Virus NS2B/NS3 protease as an antiviral target.
Chappell KJ; Stoermer MJ; Fairlie DP; Young PR
Curr Med Chem; 2008; 15(27):2771-84. PubMed ID: 18991636
[TBL] [Abstract][Full Text] [Related]
19. NMR analysis of the dynamic exchange of the NS2B cofactor between open and closed conformations of the West Nile virus NS2B-NS3 protease.
Su XC; Ozawa K; Qi R; Vasudevan SG; Lim SP; Otting G
PLoS Negl Trop Dis; 2009 Dec; 3(12):e561. PubMed ID: 19997625
[TBL] [Abstract][Full Text] [Related]
20. NMR study of complexes between low molecular mass inhibitors and the West Nile virus NS2B-NS3 protease.
Su XC; Ozawa K; Yagi H; Lim SP; Wen D; Ekonomiuk D; Huang D; Keller TH; Sonntag S; Caflisch A; Vasudevan SG; Otting G
FEBS J; 2009 Aug; 276(15):4244-55. PubMed ID: 19583774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
